Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 5, 2008, Pages 1282-1289

  Bowsher, Ronald R ^a,b   Sailstad, Jeffrey M ^c  

^a B2S Consulting   (United States)

^b Millipore Corporation   (United States)

^c Sailstad and Associates Inc   (United States)

Author keywords

Analytical validation; Biomarkers; Clinical drug development; Diagnostics; Immunoassays; Osteoprotegerin; Receptor activator of nuclear factor B

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

CELL DIFFERENTIATION; CELL MATURATION; COMPLEX FORMATION; CONJUGATION; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MACROMOLECULE; OSTEOBLAST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SERODIAGNOSIS; STEM CELL; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; IMMUNOASSAY; OSTEOPROTEGERIN; RANK LIGAND; REAGENT KITS, DIAGNOSTIC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REPRODUCIBILITY OF RESULTS; RESEARCH; SOLUBILITY;

EID: 58249134378     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.09.026     Document Type: Review

References (44)

1. Williams S.A., Slavin D.E., Wagner J.A., and Webster C.J. Nat. Rev. Drug Discov. 5 (2006) 897-902
2. US Department of Health & Human Service, FDA, (March 2004) http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.
3. Colburn W.A. J. Clin. Pharmacol. 43 (2003) 329-341
4. Wagner J.A., Williams S.A., and Webster C.J. Clin. Pharmacol. Ther. 81 (2007) 104-107
5. Rifai N., Gillette M.A., and Carr S.A. Nat. Biotechnol. 24 (2006) 971-983
6. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., et al. Pharm. Res. 9 (1992) 588-592
7. Guidance for Industry on Bioanalytical Method Validation, Federal Reg. 66 (2001) 28526-28527, www.fda.gov/cder/guidance/4252fnl.pdf.
8. Lee J.W., Smith W.C., Nordblom G.D., and Bowsher R.R. In: Bloom J.C., and Dean R.A. (Eds). Validation of Assays for the Bioanalysis of Novel Biomarkers: Practical Recommendations for Clinical Investigation of New Drug Entities (2003), Marcel Dekker, Inc., New York 119-148
9. Bowsher R.R., and Smith W.C. AAPS Newsmag. 5 (2002) 18-25
10. Lee J.W., Devanarayan V., Barrett Y.U., Weiner R., Allinson J., Fountain S., et al. Pharm. Res. 23 (2006) 312-328
11. Vega D., Mallouf N.M., and Sakhaee K. J. Clin. Endocrinol. Metab. 92 (2007) 4514-4521
12. Boyce B.F., and Xing L. Arthritis Res. Ther. 9 Suppl. 1, S1 (2007) 1-7
13. Roodman G.D., and Dougall W.C. Cancer Treat. Rev. 34 (2008) 92-101
14. Rogers A., and Eastell R. J. Clin. Endocrinol. Metab. 90 (2005) 6323-6331
15. Dovio A., Data V., and Angeli A. J. Endocrinol. Invest. 28 Suppl. 10 (2005) 14-22
16. Roodman G.D. Bone Marrow Transplant. 40 (2007) 1139-1146
17. Hamdy N.A. Curr. Opin. Invest. Drugs 8 (2007) 299-303
18. Schwarz E.M., and Ritchlin C.T. Arthritis Res. Ther. 9 Suppl. 1, S7 (2007) 1-6
19. Cohen S. Arthritis Rheum. 55 (2006) 15-18
20. Sipos W., Pietschmann P., and Rauner M. Curr. Med. Chem. 15 (2008) 127-136
21. Walsh M.C., and Choi Y. Cytokine Growth Factor Rev. 14 (2003) 251-263
22. Khosla S. Endocrinology 142 (2001) 5050-5055
23. Aubin J.E., and Bonnelye E. Osteoporos. Int. 11 (2000) 905-913
24. Schneeweis L.A., Willard D., and Milla M.E. J. Biol. Chem. 280 (2005) 41155-41164
25. Ikeda T., Kasai M., Utsuyama M., and Hirokawa K. Endocrinology 142 (2001) 1419-1426
26. Yasuda H., Nakagawa N., Kinosaki M., Mochizuki S., Tomoyasu A., et al. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3597-3602
27. Mezquita-Raya P., de la Higuera M., Fernandez Garcia D., Alonso G., Estrella Ruiz-Requena M., de Dios Luna J., et al. Osteoporos. Int. 16 (2005) 1368-1374
28. Granchi D., Pellacani A., Spina M., Cenni E., Savarino L.M., Baldini N., and Giunti A. J. Bone Joint Surg. 88 (2006) 1501-1509
29. Trofimov S., Pantsulaia I., Kobyliansky E., and Livshits G. Eur. J. Endocrinol. 150 (2004) 305-311
30. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., and Bowsher R.R. J. Pharm. Biomed. Anal. 21 (2000) 1249-1273
31. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Am. J. Pathol. 165 (2003) 2021-2031
32. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. Arthritis Rheum. 46 (2002) 1744-1753
33. Hawa G., Brinskelle-Schmal N., Glatz K., Maitzen S., and Woloszczuk W. Clin. Lab. 49 (2003) 461-463
34. Buxton E.C., Yao W., and Lane N.E. J. Clin. Endocrinol. Metab. 89 (2004) 3332-3336
35. Schett G., Kiechl S., Redlich K., Oberhollenzer F., Weger S., Egger G., et al. JAMA 291 (2004) 1108-1113
36. Kraj M., Owczarska K., Sokolowska U., Centkowski P., Poglod R., and Kruk B. Arch. Immunol. Ther. Exp. 53 (2005) 454-464
37. Abrahamsen B., Hjeimborg J.B., Kostenuik P., Stilgren L.S., Kyvik K., Adamu S., et al. Bone 36 (2005) 727-735
38. Kiechl S., Schett G., Schwaiger J., Seppi K., Eder P., Egger G., et al. Circulation 116 (2007) 385-391
39. Biomedica Gruppe, Cat. no. BI-20422H (rev. no. 301004).
40. Hofbauer L.C., Schoppet M., Schuller P., Viereck V., and Christ M. Clin. Endocrinol. 60 (2004) 214-219
41. Masi L., Simonini G., Piscitelli E., Del Monte F., Giani T., Cimaz R., Vierucci S., Brandi M.L., and Falcini F. J. Rheumatol. 31 (2004) 986-991
42. Avbersek-Luznik I., Balon B.P., Rus I., and Marc J. Nephrol. Dial. Transplant. 20 (2005) 566-570
43. D'Amelio P., Grimaldi A., Di Bella S., Tamone C., Brianza S.Z., Ravazzoli M.G., et al. J. Bone Mineral Res. 23 (2008) 373-379
44. Immundiagnostik-Apotech Manual, Total sRANKL, soluble (human) ELISA kit (2006) APO-54N-016-KI01.